Drug prices
Finally! Humira’s biosimilars also hit the us market!
Humira was first marketed in 2002 and was protected in the US market until 2023, thanks to AbbVie’s use of two strategies :
Andre Wencker
September 21, 2023
Humira was first marketed in 2002 and was protected in the US market until 2023, thanks to AbbVie’s use of two strategies :
After wrapping up the 2023 enrollment, employers are now planning their next moves to mitigate the continuously growing healthcare costs impacting their plans. This is particularly true for pharmacy costs.
PhRMA, a Big Pharma lobbying group, released an advertising touting that drug prices were not fueling inflation. To prove it, they produce the graphic below.
100 million Americans, insured or not, are saddled with medical debt, a recent survey by Kaiser Family Foundation established.
US brand drug prices highest of developed countries despite clouds of smoke from big pharma and the pbm oligopoly.
What employers and their consultants need to know to make the right decisions on their prescription drug plans.
What employers and their consultants need to know to make the right decisions on their prescription drug plans.
We could have titled this part: “Forget about rebates!”, but this would have been misleading: rebates are here to stay but many experts say the major part of it is now passed over to the plans.
Care2Care International supports the Brussels Principles on the Sales of Medicines over the Internet, an initiative of the New-York based, non-profit organization, the Prescription Justice Institute.
Health Benefits Strategy: Opportunities & Risks for the C-Suite.
Ranking Hospitals And Rating The Raters. In Part 1 We Introduced The 4 Top “Producers” Of Hospital Ratings.
People interested in healthcare policy or insurance may remember this title from the late Uwe Reinhardt, a Princeton professor in Economy and expert in healthcare policy: ”it’s the prices, stupid!”, in reference to Bill Clinton’s campaign slogan: “it’s the economy, stupid!”.
Care2Care secured a strategic partnership with an innovative, transparent, 100% pass-through PBM.
Adding to our expertise in international drug sourcing, we expand our offer to the full pharmacy benefit management.
